We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current GIS market cap is 114.47B. The company's latest EPS is USD 0.3854 and P/E is 271.25.
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 24.69B | 27.31B | 27.28B | 27.12B | 28.75B |
| Operating Income | 4.07B | 9.92B | 7.33B | 7.61B | 1.66B |
| Net Income | 123M | 6.23B | 4.59B | 5.67B | 480M |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 68.41B | 67.95B | 63.17B | 62.13B | 59B |
| Total Liabilities | 50.19B | 46.89B | 41.96B | 39.38B | 39.75B |
| Total Equity | 18.22B | 21.06B | 21.21B | 22.75B | 19.25B |
| Year End December 30 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | 8.17B | 11.38B | 9.07B | 8.01B | 10.83B |
| Investing | -14.62B | -3.13B | -2.47B | -2.27B | -3.45B |
| Financing | 770M | -8.88B | -6.47B | -5.13B | -3.43B |
| Market Cap | 114.47B |
| Price to Earnings Ratio | 271.25 |
| Price to Sales Ratio | 4.53 |
| Price to Cash Ratio | 13.03 |
| Price to Book Ratio | 6.76 |
| Dividend Yield | 3.91% |
| Shares Outstanding | 1.25B |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0.22 (0.24%) |
| Company Name | Gilead Sciences Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.gilead.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
